VivoSeq
Respiratory

Acute Respiratory Distress Syndrome

104

Pipeline Programs↗

32

Active Trials↗

55

Companies Involved↗

Acute Respiratory Distress Syndrome is a highly competitive landscape with 104 programs across 55 companies. The most active players are Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Asia Cell Therapeutics (Shanghai) Co., Ltd.. 19 therapies are approved with 24 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

72/100

Pipeline Velocity

37/100

Mech. Concentration

14/100

Completion Rate

52/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Cartesian Therapeutics

1 program

Phase 1M

Meridigen Biotech Co., Ltd.

1 program

Phase 1A

Asia Cell Therapeutics (Shanghai) Co., Ltd.

1 program

Phase 1J

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

1 program

Phase 1Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

Phase 1Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical12

Ruxolitinib

Incyte

Nacl

Bayer

Angiotensin II

La Jolla Pharmaceutical Company

Remestemcel-L

Mesoblast, Ltd.

Nebulization

Tanta University

Phase 113

Tenecteplase

Roche

Methylene Blue

Provepharm SAS

Mesenchymal Stem Cells

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

Defibrotide

Jazz Pharmaceuticals

Mesenchymal Stromal Cells

Mario Negri Institute for Pharmacological Research

Phase 236

Adenosine

Astellas

Anakinra

Swedish Orphan Biovitrum

Ulinastatin

Techpool Bio-Pharma Co., Ltd.

Budesonide

Salix

Decitabine

Sun Pharma

Phase 324

Alteplase

Roche

Esmolol

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Ravulizumab

AstraZeneca

Methylprednisolone

Pfizer

Hydroxychloroquine

Alnylam Pharmaceuticals

Approved19

Propofol

Fresenius Kabi Oncology Ltd.

Naltrexone

Teva

Ketamine

Aultman Health Foundation

Losartan

Organon and Co

Desflurane

Baxter Healthcare Corporation

Analysis

Modality Breakdown

83%

Small molecule

101 of 122 classified programs — the dominant modality here.

17%ALL OTHERSCell therapy119%Monoclonal antibody43%Protein / enzyme32%Peptide32%

Small molecule leads; the ring shows all 122 classified programs, each share of the total. Modality classified for 100% of 147 pipeline programs.

Analysis

Trial Status

134

clinical trials

Completed39 · 29%
Unknown status26 · 19%
Terminated22 · 16%
Recruiting19 · 14%
Withdrawn12 · 9%
Not yet recruiting7 · 5%
Other9 · 7%

Clinical Trials

Trial Activity

134 trials

Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
Recruiting·DDirect Biologics, LLC·Phase 3·NCT05354141·970 enrolled
Surfactant for Neonatal Respiratory Distress Syndrome(NRDS) and Neonatal Acute Respiratory Distress Syndrome(NARDS)
Recruiting·—·N/A·NCT04777760·400 enrolled
A Comparative Study of Glucocorticoids Efficacy in Acute Respiratory Distress Syndrome
Recruiting·FFayoum University·Phase 2/3·NCT06496997·300 enrolled
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
Recruiting·BBioAegis Therapeutics Inc.·Phase 2·NCT05947955·600 enrolled
Metoprolol in Acute Respiratory Distress Syndrome (MAIDEN)
Recruiting·CConsorcio Centro de Investigación Biomédica en Red (CIBER)·Phase 3·NCT05847517·350 enrolled
Effect of Esmolol on Oxygenation Index in Patients With Acute Respiratory Distress Syndrome
Recruiting·—·Phase 3·NCT06013319·178 enrolled
The Effect of Erythropoietin on Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome
Recruiting·SSecond Affiliated Hospital of Wenzhou Medical University·N/A·NCT05857891·40 enrolled
To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome
Recruiting·SStaidson (Beijing) Biopharmaceuticals Co., Ltd·Phase 3·NCT07208591·406 enrolled
Effect of Different Depths of Neuromuscular Blockade on Respiratory Mechanics in Patients With Moderate-severe Acute Respiratory Distress Syndrome
Recruiting·SSoutheast University, China·N/A·NCT06514209·20 enrolled
Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury
Recruiting·—·Phase 2/3·NCT07086755·1,100 enrolled
A Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection for the Treatment of Severe Acute Respiratory Distress Syndrome
Recruiting·CChangchun Tuohua Pharmaceutical Co., Ltd.·Phase 1/2·NCT07413978·36 enrolled
Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome (THYTECH2)
Recruiting·HHospital General Universitario Gregorio Marañon·Phase 1/2·NCT06052436·24 enrolled
Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)
Recruiting·PPEACHES BIOTECH·Phase 1/2·NCT06684379·50 enrolled
Volatile Sedation for Patients With the Acute Respiratory Distress Syndrome
Recruiting·GGuy's and St Thomas' NHS Foundation Trust·Phase 2/3·NCT06014138·20 enrolled
Validation and Precision Treatment of Inflammatory Subphenotypes in Acute Respiratory Distress Syndrome: A Multicenter Cohort Study
Recruiting·SSoutheast University, China·N/A·NCT07289711·500 enrolled
Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)